Reflection paper on the EU Pharmaceutical Strategy

The BEAM Alliance welcomes the European Commission’s Pharmaceutical Strategy, which recognises the development of novel antimicrobials as a prime example of an unmet medical need and proposes important measures to address the rising threat of antimicrobial resistance (AMR),
which requires urgent action. We count on the Commission to foster short-term solutions in parallel to long-term incentive reforms, and to consider the specific challenges faced by European small and medium-sized enterprises (SMEs) in the field. Europe’s preparedness for the next global health crisis may be tested sooner than its legislative pace can keep up with.